The company said enrollment in its Phase 3 HyBryte study is progressing well, with an interim efficacy analysis planned for ...
Investors reacted to the company’s leadership shake-up and new data from its ulcerative colitis therapy Omvoh showing ...
This is a solid paper on intermittent fasting that will be of interest to readers. The data presented are certainly valuable as a resource. The findings of both shared and tissue-specific signatures, ...